Appetite Control

Semaglutide

A GLP-1 receptor agonist that blocks cravings, slows digestion, and helps you get full sooner and stay full longer.

  • No Insurance Required

  • Ships From USA Pharmacy

  • Free Medical Consultation

  • Syringes Included

  • No Subscription Required

  • Licensed Provider

  • Licensed Pharmacy

  • HIPAA Compliant

  • LegitScript Certified

Overview

GLP-1 Receptor Agonist

Semaglutide is a synthetic analog of human glucagon-like peptide-1. It binds to GLP-1 receptors in the brain, gut, and pancreas to regulate appetite, gastric motility, and glucose metabolism.

Mechanism of Action

Slows gastric emptying, suppresses glucagon secretion, enhances glucose-dependent insulin release, and reduces appetite signaling in the hypothalamus. The result is reduced caloric intake, improved blood sugar control, and sustained weight loss.

Injection

Administered subcutaneously once weekly.

Information presented here is for educational purposes only and not intended to replace or substitute guidance from a healthcare provider. Compounded products are not FDA-approved nor evaluated by the FDA for safety, efficacy, or quality.

Benefits

Weight Loss

Reduction in body weight when combined

with reduced caloric intake and physical activity.

Reduced Cravings & Hunger

Acts on GLP-1 receptors in the hypothalamus to suppress appetite signaling and reduce food-seeking

behavior, particularly for high-calorie foods.

Full Sooner, Stay Full Longer

Slows gastric emptying so food remains in the stomach longer, increasing satiety per meal and reducing overall caloric intake without forced restriction.

Improved Insulin Sensitivity

Enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses inappropriate glucagon release, improving how the body processes and stores glucose.

Reduces Gut Inflammation

Reduce intestinal inflammation and support gut barrier integrity, contributing to improved gastrointestinal function.

Improved Nutrient Absorption

Slower gastric transit allows more complete digestion and absorption of nutrients from food.

Individual results may vary. Benefits described are based on clinical and pharmacological evidence and do not constitute a guarantee of treatment outcomes. All treatment requires evaluation and approval by a licensed provider.

GLP-1 Receptor Agonist

Semaglutide

A 31-amino-acid GLP-1 analog engineered with two structural modifications — an Aib substitution at position 2 blocking DPP-4 cleavage, and a C18 fatty diacid chain at position 20 enabling albumin binding — extending half-life to 168 hours and enabling once-weekly subcutaneous dosing with sustained receptor engagement across all target tissues.

FDA Approved — Ozempic / Wegovy
GLP-1R Agonist
Once Weekly SQ
168
hours
Half-Life — Weekly Dosing
14.9
% body weight
Mean Reduction STEP 1 (68 wk)
0.25→2.4
mg weekly SQ
Dose Titration Range
94
% homology
Native GLP-1 Sequence Match
Molecular Structure
31-Residue GLP-1 Analog — Two Key Modifications
MW ~4113 Da
Aib mod (DPP-4 block)
K* C18 FA chain (albumin binding)
Lys→Arg mod
Nonpolar / Aromatic
Polar uncharged
Acidic (D, E)
Basic (H, R, K)
Mechanism of Action
SQ Depot → Albumin Binding → Multi-Tissue GLP-1R Activation
SQ Depot
Subcutaneous injection forms depot; slow Tmax ~24–36 hr
›
Albumin Binding
C18 fatty diacid via Glu-Glu-mini-PEG linker binds Lys-525 on HSA; extends t½ to 168 hr
›
GLP-1R / cAMP-PKA
Gs-coupled GPCR; activates adenylyl cyclase → cAMP ↑ → PKA → multiple downstream effects
›
Pancreas
Glucose-dependent insulin ↑
Glucagon ↓ (α-cells)
Hypothalamus
ARC/PVN GLP-1R → appetite ↓ satiety ↑ ~35% caloric intake ↓
GI Tract
Gastric emptying ↓ — slows glucose absorption, prolongs satiety
Efficacy Profile
Multi-Domain Radar
Semaglutide 2.4 mg/wk
Clinical Trial Data
Key Outcome Results
Body Weight — STEP 1 Trial
Wk 16
−8.2%
Wk 36
−12.1%
Wk 68
−14.9%
HbA1c Reduction — SUSTAIN
1 mg/wk
−1.5%
2 mg/wk
−1.8%
Cardiovascular — SELECT Trial
HHF
−13%
MACE
−20%
Renal — FLOW Trial
UACR
−23%
eGFR
−24%
Pharmacokinetic + Clinical Timeline
Weekly PK Profile & 68-Week Efficacy Arc
Pharmacokinetics — 1 Week
Semaglutide Plasma Level
Inj.
Absorption
Peak Tmax
Albumin-Bound Plateau
Trough
GLP-1R Engagement
Min.
Rising
Sustained Full Engagement
Appetite Suppression
None
Begin
Active Hunger Suppression
Hr 0
Hr 12
Hr 24
Hr 72
Hr 168
Clinical Outcomes — 68 Weeks
Body Weight Reduction
Adapt.
−3% Early
Progressive −8→12%
Max −14.9%
Metabolic Improvements
Base
HbA1c↓
BP↓ Lipids↓
CV + Renal
GI Side Effects Profile
Peak GI (nausea peak)
Resolving
Tolerability Established
Wk 0
Wk 4
Wk 16
Wk 36
Wk 68
Significant Weight Loss
Mean 14.9% body weight reduction over 68 weeks (STEP 1 trial, 2.4 mg/wk). Responders exceeding 20% reduction: ~32% of participants. Effect sustained with continued dosing.
Appetite & Satiety Control
Hypothalamic GLP-1R activation in the arcuate nucleus (ARC) and paraventricular nucleus (PVN) reduces caloric intake by approximately 35%. Prolongs satiety signals via vagal afferent pathways.
Glycemic Control
Glucose-dependent insulin secretion (safe — no hypoglycemia when glucose is normal) + glucagon suppression via pancreatic α-cell GLP-1R. HbA1c reduction up to 1.8% (SUSTAIN 6).
Cardiovascular Protection
20% reduction in MACE events (SELECT trial — 17,604 non-diabetic overweight adults, 3.3 yr follow-up). Reduces systolic BP ~6 mmHg and improves lipid profile independent of weight loss.
Renal Protection
24% reduction in major kidney disease events (FLOW trial — first dedicated GLP-1 renal outcomes study). 23% reduction in UACR. Direct GLP-1R expression in renal proximal tubule cells mediates protection.
Once-Weekly Dosing
168-hour half-life achieved via the C18 fatty diacid albumin-binding modification at K26, eliminating daily dosing burden. Single subcutaneous injection maintains therapeutic plasma levels for the full 7-day cycle.
Medical Supervision Required. Semaglutide (Ozempic — 0.5–2 mg/wk; Wegovy — 0.25–2.4 mg/wk) is FDA-approved for T2D glycemic control and chronic weight management respectively. Contraindications: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — GLP-1R agonists cause dose-dependent thyroid C-cell tumors in rodents; human risk undetermined. GI side effects (nausea, vomiting, diarrhea) are most common during titration and generally resolve within 4–8 weeks; slow titration (0.25 mg → 0.5 → 1 → 1.7 → 2.4 mg at 4-week intervals) is strongly recommended. Pancreatitis risk: discontinue if suspected. STEP 4 withdrawal data showed substantial weight regain after discontinuation — this is a chronic therapy requiring ongoing prescribing. Not for use in patients with T1D or as first-line for T2D. All prescribing requires clinical evaluation, current labs, and documented BMI/comorbidity indication.

Simple. Medical.

Personalized.

Medical intake

Answer a few online questions about your health history, lifestyle, & goals. No clinic visits required.

Provider evaluation

A licensed medical provider reviews your intake to determine the safest, personalized treatment.

Personalized plan

Custom treatment plan built around your unique health needs, goals, medical history, & biology.

Ongoing support

Stay connected with your care team for follow-ups, adjustments, & expert answers 100% online.

FAQs

What is Semaglutide?

Semaglutide is a prescription therapy used for weight management and appetite regulation.

Who should use Semaglutide?

Patients seeking support for weight management and appetite regulation may qualify after evaluation by a licensed provider.

Does Semaglutide require a prescription?

Yes. Semaglutide is a compounded prescription preparation dispensed pursuant to a valid prescription from a licensed healthcare provider. A telehealth consultation, medical intake, and provider evaluation are required to screen for contraindications and establish an individualized titration protocol.

What are the possible side effects?

Common side effects are predominantly gastrointestinal and most frequent during dose escalation — including nausea, vomiting, diarrhea, constipation, abdominal discomfort, reduced appetite, and dyspepsia. Most patients find these effects diminish as the body adjusts to each dose level. Injection site reactions may occur. Hypoglycemia risk is low when Semaglutide is used alone but increases significantly when combined with insulin or sulfonylureas. Post-marketing reports have described mood changes in some patients on GLP-1 agents; those with a psychiatric history should be monitored. Report all side effects to your provider promptly.

Who should not use Semaglutide?

Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Patients with known hypersensitivity to semaglutide, cyanocobalamin, or any component of the formulation should not use this preparation. Those with Leber's hereditary optic neuropathy should not receive cyanocobalamin-containing preparations without specialist evaluation. This medication is contraindicated during pregnancy. Patients with a history of pancreatitis, severe gastroparesis, or significant renal or hepatic dysfunction require individualized provider assessment.

Are there any drug interactions?

Semaglutide's gastric-emptying delay can reduce absorption and alter timing of orally administered medications including oral contraceptives, thyroid hormone, and warfarin. Patients on insulin or sulfonylureas face elevated hypoglycemia risk when Semaglutide is added — dose reductions of those agents are often needed. Metformin reduces B12 absorption over time, making the cyanocobalamin component particularly relevant for patients on this medication. Discuss all current medications with your provider before beginning treatment.

Is Semaglutide safe if I have a pre-existing medical condition?

Patients with a personal or family history of medullary thyroid carcinoma or MEN2 must not use Semaglutide. Those with type 1 diabetes, pancreatitis history, or significant renal or hepatic conditions require careful individualized review. Patients with cardiovascular disease may be treated under close provider supervision. Your provider requires a complete medical history before prescribing and will determine suitability based on your individual profile.

Contact Us

Text or Call

Hours

Monday–Saturday, 10am–8pm ET

Text or Call

Hours

Monday–Saturday, 10am–8pm ET

Start Your Journey

Start Your

Weight Loss Journey

Physician-supervised. Delivered to your door.

No clinic visits required.

  • Licensed Provider

  • Licensed Pharmacy

  • HIPAA Compliant

  • LegitScript Certified

© 2026, Skinny Rich Shot®

[email protected]

text (323)-283-9219

638 1/2 N. Robertson Blvd, West Hollywood, CA 90069

Available in select U.S. states. Eligibility is determined by the provider. Compounded semaglutide and tirzepatide are not FDA-approved for weight loss. It is prescribed only when deemed medically appropriate by a licensed provider after review. Individual results vary significantly based on factors like adherence, diet, exercise, and health status. No guarantees of weight loss. GLP-1 medications like semaglutide may increase the risk of thyroid C-cell tumors based on animal studies; human risk is not confirmed. Services provided by licensed physicians/nurse practitioners in states served, e.g., CA, FL, and others, via telemedicine. Check your state's telemedicine laws. We prioritize your privacy and comply with HIPAA regulations for protected health information. Must be 18 or older.